Alpha-Dihydroartemisinin CAS#81496-81-3
Rapid and effective antimalarial activity – Strongly kills asexual forms of Plasmodium and quickly controls symptoms.
Efficacy against drug-resistant strains – Effective against chloroquine- and piperaquine-resistant falciparum malaria.
Low toxicity and good oral absorption – Safe profile with high bioavailability when administered orally.
Broad clinical application – Used for various types of malaria, including severe cerebral and drug-resistant falciparum malaria.
Products Description of alpha-Dihydroartemisinin CAS#81496-81-3
Dihydroartemisinin exhibits potent activity against the asexual forms of Plasmodium, rapidly controlling symptoms and eliminating various asexual stages of the parasite. It is also effective against falciparum malaria resistant to chloroquine and piperaquine, with low toxicity. Animal studies indicate that administration during the pregnancy induction period in mice can increase fetal occurrence of chemicalbook but does not cause teratogenic effects. The compound has good oral bioavailability; when administered orally at 2 mg/kg, tmax is 1.33 hours and Cmax is 0.71 μg/mL. Clinically, it is used to treat multiple forms of malaria, particularly severe and cerebral falciparum malaria resistant to chloroquine and piperaquine.
Parameters
| Melting point | 142-144°C |
| Boiling point | 375.6±42.0 °C(Predicted) |
| density | 1.24±0.1 g/cm3(Predicted) |
| storage temp. | 2-8°C |
| solubility | Chloroform (Slightly), DMSO (Slightly), Ethyl Acetate (Slightly), Methanol (Slightly) |
| form | Solid |
| pka | 12.61±0.70(Predicted) |
| color | White to Off-White |
| Alpha-Dihydroartemisinin Usage And Synthesis | |
| Chemical Properties | White needle like crystal |
| Uses | antimalarial, antiinflammatory |
| Definition | ChEBI: Dihydroartemisinin (DHA) is an artemisinin derivative. |
| target | Antifection |
Product Application of alpha-Dihydroartemisinin CAS#81496-81-3
Dihydroartemisinin is used to treat various types of malaria, particularly chloroquine- and piperaquine-resistant falciparum malaria, as well as severe cerebral malaria.
